Literature DB >> 16530420

Histopathology of BRCA1- and BRCA2-associated breast cancer.

Emiliano Honrado1, Javier Benítez, José Palacios.   

Abstract

Hereditary breast carcinomas that are attributable to BRCA1/2 mutations have their own morphological and immunohistochemical characteristics. BRCA1-associated carcinomas are poorly differentiated infiltrating ductal carcinomas that frequently show morphological features of typical or atypical medullary carcinoma. BRCA2-associated breast carcinomas tend to be of higher grade than sporadic age-matched controls. BRCA1tumors have been found to be more frequently estrogen receptor- and progesterone receptor-negative, and p53-positive than are age-matched controls, whereas these differences are not usually found in BRCA2-associated tumors. In addition, BRCA1- and BRCA2-associated breast carcinomas show a low frequency of HER2 expression. Most BRCA1 breast carcinomas are characterized by the expression of basal (myoepithelial) markers, such as cytokeratin 5/6 and or P-cadherin. These features could be used to distinguish patients who are likely to carry a BRCA1 or BRCA2 germline mutation, thus indicating which gene should be screened for first in families with a high incidence of breast and ovarian cancer.

Entities:  

Mesh:

Year:  2006        PMID: 16530420     DOI: 10.1016/j.critrevonc.2006.01.006

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  28 in total

Review 1.  Genomic instability in breast cancer: pathogenesis and clinical implications.

Authors:  Kevin A Kwei; Yvonne Kung; Keyan Salari; Ilona N Holcomb; Jonathan R Pollack
Journal:  Mol Oncol       Date:  2010-04-09       Impact factor: 6.603

2.  Proteomic studies in breast cancer (Review).

Authors:  Xian-Ju Qin; Bruce X Ling
Journal:  Oncol Lett       Date:  2012-01-18       Impact factor: 2.967

3.  Clinical and pathological characteristics of Hispanic BRCA-associated breast cancers in the American-Mexican border city of El Paso, TX.

Authors:  Zeina Nahleh; Salman Otoukesh; Alok Kumar Dwivedi; Indika Mallawaarachchi; Luis Sanchez; J Salvador Saldivar; Kayla Cataneda; Rosalinda Heydarian
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

Review 4.  Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers.

Authors:  Kelly C Gast; Paul V Viscuse; Somaira Nowsheen; Tufia C Haddad; Robert W Mutter; Andrea E Wahner Hendrickson; Fergus J Couch; Kathryn J Ruddy
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-01

5.  Pathological characteristics of BRCA-associated breast cancers in Hispanics.

Authors:  Veronica I Lagos-Jaramillo; Michael F Press; Charité N Ricker; Louis Dubeau; Phuong L Mai; Jeffrey N Weitzel
Journal:  Breast Cancer Res Treat       Date:  2011-05-21       Impact factor: 4.872

Review 6.  Genotype/Phenotype correlations in patients with hereditary breast cancer.

Authors:  Maike Wittersheim; Reinhard Büttner; Birgid Markiefka
Journal:  Breast Care (Basel)       Date:  2015-02       Impact factor: 2.860

7.  Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy.

Authors:  Yvonne Hui-Fang Teng; Wai-Jin Tan; Aye-Aye Thike; Poh-Yian Cheok; Gary Man-Kit Tse; Nan-Soon Wong; George Wai-Cheong Yip; Boon-Huat Bay; Puay-Hoon Tan
Journal:  Breast Cancer Res       Date:  2011-04-01       Impact factor: 6.466

8.  Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.

Authors:  Andrew D Spearman; Kevin Sweet; Xiao-Ping Zhou; Jane McLennan; Fergus J Couch; Amanda Ewart Toland
Journal:  J Clin Oncol       Date:  2008-09-29       Impact factor: 44.544

9.  Lympho-vascular invasion in BRCA related breast cancer compared to sporadic controls.

Authors:  Marise R Heerma van Voss; Petra van der Groep; Jos Bart; Elsken van der Wall; Paul J van Diest
Journal:  BMC Cancer       Date:  2010-04-16       Impact factor: 4.430

10.  The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression.

Authors:  Reena Shakya; Matthias Szabolcs; Ellen McCarthy; Elson Ospina; Katia Basso; Subhadra Nandula; Vundavalli Murty; Richard Baer; Thomas Ludwig
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.